Rhode Island Patent of the Month – February 2023
While medicine is crucial to treat a range of ailments – from disease to chronic pain – the same active agents that help us can also be addictive. There are many cases where individuals abuse pharmaceuticals, including extracting the active agent to get a more potent form. In an effort to limit this abuse, Rhodes Pharmaceuticals LP has created a tamper-resistant pharmaceutical composition. The pharmaceutical product includes an ion exchange resin and an active agent that releases about 75% or more of the agent within an hour.
Immediate release dosage forms are easily abused, allowing the active agent to be taken with immediate effects. By achieving a slow and controlled release, the recreational – and abusive – use of the compound is limited, ensuring an individual can’t reach that high they are looking for. The ion exchange resin also ensures the active agent won’t be released unless the compound is in an environment that resembles gastric fluid. This means placing the pill or tablet in alcohol or other aqueous fluids won’t be sufficient to pull out the active agent, and an individual can’t extract the active agent preemptively.
This type of product is vital in the treatment of pain and attention deficit hyperactivity disorder (ADHD), where there is a higher risk of abuse. The pharmaceutical composition is an oral dosage form that has been tested in vitro for dissolution in a USP Apparatus 2 (paddle) at about 50 rpm in about 900 ml 0.1N HCl at about 37° C.
Rhodes Pharmaceuticals is a pharmaceutical company that focuses on providing high-quality, affordable generic drugs. Their goal is to bring innovative solutions to the market and provide patients with the best possible care. The development of this pharmaceutical composition is a testament to their commitment to innovation and care.
Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.
